SEARCH
Toggle navigation
HOME
COMPANY
BOARD OF DIRECTORS
MANAGEMENT
PARTNERSHIPS
CAREERS
VACCINES
MODITOPE
Modi-1
Modi-2
IMMUNOBODY
SCIB1 & iSCIB1+
SCIB2 & iSCIB2
COVIDITY
VACCINE PUBLICATIONS
ANTIBODIES
GLYMAB
ANTI-GLYCAN MAB
AVIDIMAB
ANTIBODY PUBLICATIONS
INVESTORS
COMPANY PROFILE
ADVISORS
CORPORATE GOVERNANCE
DIRECTORS
DOCUMENTS & PRESENTATIONS
SHARE INFO
FINANCIAL INFO
2023 CAPITAL RAISE
2020 CAPITAL RAISE
REGULATORY NEWS
REGULATORY NEWS ARCHIVE
NEWS
LATEST NEWS
INTERVIEWS
MEDIA COVERAGE
WEBCASTS
YEAR - 2024
YEAR - 2023
YEAR - 2022
YEAR - 2021
YEAR - 2020
YEAR - 2019
YEAR - 2018
YEAR - 2017
YEAR - 2016
CONTACT US
SEARCH
INVESTORS
HOME
COMPANY
BOARD OF DIRECTORS
MANAGEMENT
PARTNERSHIPS
CAREERS
VACCINES
MODITOPE
Modi-1
Modi-2
IMMUNOBODY
SCIB1 & iSCIB1+
SCIB2 & iSCIB2
COVIDITY
VACCINE PUBLICATIONS
ANTIBODIES
GLYMAB
ANTI-GLYCAN MAB
AVIDIMAB
ANTIBODY PUBLICATIONS
INVESTORS
COMPANY PROFILE
ADVISORS
CORPORATE GOVERNANCE
DIRECTORS
DOCUMENTS & PRESENTATIONS
SHARE INFO
FINANCIAL INFO
2023 CAPITAL RAISE
2020 CAPITAL RAISE
REGULATORY NEWS
REGULATORY NEWS ARCHIVE
NEWS
LATEST NEWS
INTERVIEWS
MEDIA COVERAGE
WEBCASTS
YEAR - 2024
YEAR - 2023
YEAR - 2022
YEAR - 2021
YEAR - 2020
YEAR - 2019
YEAR - 2018
YEAR - 2017
YEAR - 2016
CONTACT US
Investor Information
Scancell Holdings PLC is an AIM listed company
Advisors
Share Information
Corporate Governance
Financial Information
Documents & Presentations
Regulatory News
Press Releases
Scancell to present at the Annual Immuno-Oncology Summit Europe
To download
click here
Scancell to Present at 2024 AACR Annual Meeting
To download
click here
First Patient dosed with iSCIB1+ in SCOPE trial
To download
click here
View all posts
»